Synthetic Data Could Cut Pharma's Billion-Dollar Drug Development Delays

Drug development averages 10–15 years and costs over $1 billion per approved therapy, with 85% of clinical trials facing delays largely due to restricted data access. A survey of hospital researchers found that 51% cited waiting for data access as their biggest barrier to progress, more than funding or talent. Synthetic data — artificially generated datasets that mirror real patient population statistics without containing identifiable personal information — is emerging as a practical solution to this bottleneck. Unlike anonymized records, synthetic data is not legally bound by the same consent frameworks or cross-border transfer restrictions, enabling research teams to share datasets with global partners in minutes rather than months. Though long considered experimental, synthetic data is increasingly being adopted in 2026 as core infrastructure by pharma and biotech organizations seeking faster, compliance-safe research workflows.